{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:42:13Z","timestamp":1792453333349,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jconrel.2026.115455","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:01:00Z","timestamp":1792422060000},"page":"115455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanistic benchmarking of SNAC, DDM, and LLC reveals enhancer-dependent pathways for intestinal semaglutide delivery"],"prefix":"10.1016","author":[{"given":"Banghao","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye Chan","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul W.","family":"Basit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115455_bb0005","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.drudis.2006.08.005","article-title":"Is the oral route possible for peptide and protein drug delivery?","volume":"11","author":"Morishita","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2026.115455_bb0010","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.7150\/thno.61747","article-title":"Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2026.115455_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114097","article-title":"Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based nanocarriers","volume":"182","author":"Haddadzadegan","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115455_bb0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2020.05.007","article-title":"Systemic delivery of peptides by the oral route: formulation and medicinal chemistry approaches","volume":"157","author":"Brayden","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115455_bb0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijpharm.2013.02.030","article-title":"Approaches for enhancing oral bioavailability of peptides and proteins","volume":"447","author":"Renukuntla","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115455_bb0030","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tibtech.2009.07.009","article-title":"Therapeutic application of peptides and proteins: parenteral forever?","volume":"27","author":"Antosova","year":"2009","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115455_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202400843","article-title":"Gastrointestinal permeation enhancers beyond sodium caprate and SNAC - what is coming next?","volume":"11","author":"Bohley","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2026.115455_bb0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1208\/s12248-011-9307-4","article-title":"Absorption enhancers: applications and advances","volume":"14","author":"Aungst","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2026.115455_bb0045","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.addr.2016.06.005","article-title":"Intestinal permeation enhancers for oral peptide delivery","volume":"106","author":"Maher","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115455_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113925","article-title":"Formulation strategies to improve the efficacy of intestinal permeation enhancers","volume":"177","author":"Maher","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115455_bb0055","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40262-018-0728-4","article-title":"Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes","volume":"58","author":"Granhall","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.115455_bb0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115455_bb0065","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jconrel.2026.115455_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105509","article-title":"Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers","volume":"154","author":"Fattah","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115455_bb0075","article-title":"The combined effect of permeation enhancement and proteolysis inhibition on the systemic exposure of orally administrated peptides: Salcaprozate sodium, soybean trypsin inhibitor, and teriparatide study in pigs","volume":"3","author":"Burshtein","year":"2021","journal-title":"Int. J. Pharm.: X"},{"key":"10.1016\/j.jconrel.2026.115455_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123680","article-title":"Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP\/GLP1 peptide in monkeys","volume":"650","author":"Tran","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115455_bb0085","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J","article-title":"Intestinal permeation enhancers","volume":"89","author":"Aungst","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115455_bb0090","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2016.1176822","article-title":"Safety concerns over the use of intestinal permeation enhancers: a mini-review","volume":"4","author":"McCartney","year":"2016","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.jconrel.2026.115455_bb0095","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2020.04.023","article-title":"A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C10)","volume":"152","author":"Twarog","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.115455_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105685","article-title":"Comparison of the effects of the intestinal permeation enhancers, SNAC and sodium caprate (C10): isolated rat intestinal mucosae and sacs","volume":"158","author":"Twarog","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115455_bb0105","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1021\/acs.molpharmaceut.7b00297","article-title":"Dodecylmaltoside modulates bicellular tight junction contacts to promote enhanced permeability","volume":"14","author":"Gradauer","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115455_bb0110","first-page":"246","article-title":"Evaluation of Dodecylmaltoside as a permeability enhancer for insulin using human carcinoma cells","volume":"94","author":"Tirumalasetty","year":"2005","journal-title":"JPharmSci"},{"key":"10.1016\/j.jconrel.2026.115455_bb0115","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/10717541003604882","article-title":"Effect of dodecylmaltoside (DDM) on uptake of BCS III compounds, tiludronate and cromolyn, in Caco-2 cells and rat intestine model","volume":"17","author":"Deshmukh","year":"2010","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115455_bb0120","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ejps.2012.08.010","article-title":"Evaluation of alkylmaltosides as intestinal permeation enhancers: comparison between rat intestinal mucosal sheets and Caco-2 monolayers","volume":"47","author":"Petersen","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115455_bb0125","first-page":"G332","article-title":"Acylcarnitines: drug absorption-enhancing agents in the gastrointestinal tract","volume":"251","author":"Fix","year":"1986","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.jconrel.2026.115455_bb0130","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2133\/dmpk.DMPK-10-RG-071","article-title":"Absorption enhancement effect of acylcarnitines through changes in tight junction protein in Caco-2 cell monolayers","volume":"26","author":"Doi","year":"2011","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.115455_bb0135","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1023\/A:1015838508656","article-title":"Relationship between drug absorption enhancing activity and membrane perturbing effects of acylcarnitines","volume":"8","author":"LeCluyse","year":"1991","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115455_bb0140","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0039-9140(97)00017-9","article-title":"A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability","volume":"44","author":"Ishiyama","year":"1997","journal-title":"Talanta"},{"key":"10.1016\/j.jconrel.2026.115455_bb0145","series-title":"Assay Guidance Manual","article-title":"Cell Viability Assays","author":"Riss","year":"2013"},{"key":"10.1016\/j.jconrel.2026.115455_bb0150","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2026.115455_bb0155","author":"Sui"},{"key":"10.1016\/j.jconrel.2026.115455_bb0160","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/0006-291X(91)91647-U","article-title":"Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells","volume":"175","author":"Artursson","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2026.115455_bb0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0378-5173(91)90067-X","article-title":"A method for the determination of cellular permeability coefficients and aqueous boundary layer thickness in monolayers of intestinal epithelial (Caco-2) cells grown in permeable filter chambers","volume":"71","author":"Karlsson","year":"1991","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115455_bb0170","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.1618","article-title":"In vivo fluorescein isothiocyanate-dextran (FD4) permeability assay","volume":"5","author":"Watson","year":"2015","journal-title":"Bio-Protocol"},{"key":"10.1016\/j.jconrel.2026.115455_bb0175","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/03639045.2012.692376","article-title":"The effect of various absorption enhancers on tight junction in the human intestinal Caco-2 cell line","volume":"39","author":"Yu","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2026.115455_bb0180","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.3892\/mmr.2014.2126","article-title":"Effects of alcohol on intestinal epithelial barrier permeability and expression of tight junction-associated proteins","volume":"9","author":"Wang","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jconrel.2026.115455_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133926","article-title":"Remodeling of tight junctions and enhancement of barrier integrity of the CACO-2 intestinal epithelial cell layer by micronutrients","volume":"10","author":"Valenzano","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2026.115455_bb0190","author":"Sui"},{"key":"10.1016\/j.jconrel.2026.115455_bb0195","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1021\/mp500809f","article-title":"Toward Oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs","volume":"12","author":"Wang","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115455_bb0200","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejps.2015.06.018","article-title":"Stability of peptide drugs in the colon","volume":"78","author":"Wang","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115455_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123688","article-title":"Novel LC-MS\/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats","volume":"1221","author":"Lee","year":"2023","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jconrel.2026.115455_bb0210","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1023\/A:1015937605100","article-title":"Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa","volume":"7","author":"Hilgers","year":"1990","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115455_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11020078","article-title":"Intestinal permeation enhancers for oral delivery of macromolecules: a comparison between salcaprozate sodium (SNAC) and sodium caprate (C10)","volume":"11","author":"Twarog","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115455_bb0220","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jcis.2007.08.063","article-title":"pH dependence of adsorption of n-dodecyl-\u03b2-d-maltoside on solids","volume":"316","author":"Lu","year":"2007","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2026.115455_bb0225","series-title":"Solubilization of Membrane Proteins","author":"Sigma-Aldrich","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115455_bb0230","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jcis.2021.11.056","article-title":"How do chain lengths of acyl-l-carnitines affect their surface adsorption and solution aggregation?","volume":"609","author":"Liu","year":"2022","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2026.115455_bb0235","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1021\/la950670w","article-title":"Electrolyte effects on the surface tension and micellization of n-dodecyl \u03b2-d-maltoside solutions","volume":"12","author":"Zhang","year":"1996","journal-title":"Langmuir"},{"key":"10.1016\/j.jconrel.2026.115455_bb0240","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jcis.2021.01.106","article-title":"Surface adsorption and solution aggregation of a novel lauroyl-l-carnitine surfactant","volume":"591","author":"Liu","year":"2021","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2026.115455_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122131","article-title":"Characterization of the physicochemical interactions between exenatide and two intestinal permeation enhancers: sodium caprate (C10) and salcaprozate sodium (SNAC)","volume":"626","author":"Twarog","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115455_bb0250","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1091\/mbc.e09-04-0320","article-title":"ZO-1 stabilizes the tight junction solute barrier through coupling to the perijunctional cytoskeleton","volume":"20","author":"Itallie","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.jconrel.2026.115455_bb0255","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/2211068214561025","article-title":"TEER measurement techniques for in vitro barrier model systems","volume":"20","author":"Srinivasan","year":"2015","journal-title":"SLAS Technol."},{"key":"10.1016\/j.jconrel.2026.115455_bb0260","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1023\/A:1012102522787","article-title":"In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man\u2014fact or myth","volume":"14","author":"Yee","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115455_bb0265","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2017.1361900","article-title":"Intestinal surfactant permeation enhancers and their interaction with enterocyte cell membranes in a mucosal explant system","volume":"5","author":"Danielsen","year":"2017","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.jconrel.2026.115455_bb0270","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejpb.2021.11.010","article-title":"Intestinal permeation enhancers enable oral delivery of macromolecules up to 70 kDa in size","volume":"170","author":"Fein","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.115455_bb0275","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1021\/acs.molpharmaceut.2c00261","article-title":"Intestinal absorption of FITC-Dextrans and macromolecular model drugs in the rat intestinal instillation model","volume":"19","author":"Berg","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115455_bb0280","doi-asserted-by":"crossref","first-page":"9512","DOI":"10.1038\/s41467-025-64891-0","article-title":"Permeation enhancer-induced membrane defects assist the oral absorption of peptide drugs","volume":"16","author":"Colston","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115455_bb0285","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1021\/acs.molpharmaceut.0c00668","article-title":"Influence of bile composition on membrane incorporation of transient permeability enhancers","volume":"17","author":"Hossain","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115455_bb0290","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/0092-8674(92)90306-W","article-title":"The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway","volume":"70","author":"Bucci","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115455_bb0295","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1146\/annurev.biochem.78.081307.110540","article-title":"Mechanisms of endocytosis","volume":"78","author":"Doherty","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.jconrel.2026.115455_bb0300","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nature01451","article-title":"Regulated portals of entry into the cell","volume":"422","author":"Conner","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115455_bb0305","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.devcel.2006.04.002","article-title":"Dynasore, a cell-permeable inhibitor of dynamin","volume":"10","author":"Macia","year":"2006","journal-title":"Dev. Cell"},{"key":"10.1016\/j.jconrel.2026.115455_bb0310","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12964-015-0102-1","article-title":"Dynasore - not just a dynamin inhibitor","volume":"13","author":"Preta","year":"2015","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.jconrel.2026.115455_bb0315","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/acs.molpharmaceut.1c00861","article-title":"Exploring the predictive power of the in situ perfusion technique towards drug absorption: theory, practice, and applications","volume":"19","author":"Hens","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115455_bb0320","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ijpharm.2014.11.035","article-title":"In situ perfusion in rodents to explore intestinal drug absorption: challenges and opportunities","volume":"478","author":"Stappaerts","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115455_bb0325","first-page":"3136","article-title":"In situ perfusion model in rat colon for drug absorption studies: comparison with small intestine and Caco-2 cell model","volume":"104","author":"Lozoya-Agullo","year":"2015","journal-title":"JPharmSci"},{"key":"10.1016\/j.jconrel.2026.115455_bb0330","article-title":"Regional intestinal drug permeability and effects of permeation enhancers in rat","volume":"12","author":"Dahlgren","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115455_bb0335","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1021\/acs.molpharmaceut.1c00724","article-title":"Impact of intestinal concentration and colloidal structure on the permeation-enhancing efficiency of sodium caprate in the rat","volume":"19","author":"Berg","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115455_bb0340","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1042\/bj20031253","article-title":"Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis","volume":"377","author":"Rejman","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.jconrel.2026.115455_bb0345","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1021\/mp100144v","article-title":"Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids","volume":"7","author":"S\u00f6derlind","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115455_bb0350","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1021\/acs.jpcb.7b08622","article-title":"Characterization of solubilizing nanoaggregates present in different versions of simulated intestinal fluid","volume":"121","author":"Clulow","year":"2017","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.jconrel.2026.115455_bb0355","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrm.2016.80","article-title":"Tight junctions: from simple barriers to multifunctional molecular gates","volume":"17","author":"Zihni","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jconrel.2026.115455_bb0360","first-page":"3511","article-title":"Increases in bioavailability of poorly absorbed drug by acylcarnitine","volume":"101","author":"Tomita","year":"2012","journal-title":"JPharmSci"},{"key":"10.1016\/j.jconrel.2026.115455_bb0365","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41575-023-00766-3","article-title":"Paracellular permeability and tight junction regulation in gut health and disease","volume":"20","author":"Horowitz","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115455_bb0370","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0378-5173(01)00871-7","article-title":"Enteric coated HPMC capsules designed to achieve intestinal targeting","volume":"231","author":"Cole","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115455_bb0375","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/gut.39.2.299","article-title":"Variability of gastrointestinal transit in healthy women and men","volume":"39","author":"Degen","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2026.115455_bb0380","author":"Sauerberg"},{"key":"10.1016\/j.jconrel.2026.115455_bb0385","series-title":"Swiss Public Assessment Report: Rybelsus (semaglutide)","author":"Swissmedic","year":"2020"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592600859X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592600859X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:11:10Z","timestamp":1792451470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592600859X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":77,"alternative-id":["S016836592600859X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115455","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic benchmarking of SNAC, DDM, and LLC reveals enhancer-dependent pathways for intestinal semaglutide delivery","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115455"}}